Learn what medical experts have to say about PLUVICTO after only 1 ARPI1
Care Team Perspectives for a Patient With mCSPC Who Received an ARPI and Recently Progressed to mCRPC
Nuclear medicine physician Dr Phillip J. Koo, medical oncologist Dr Scott T. Tagawa, and urologist Dr Jason M. Hafron walk through the case of a patient who previously received an ARPI for mCSPC and recently progressed to mCRPC.
Medical Expert Perspectives on a Patient With mCRPC After Progression on an ARPI
Watch as nuclear medicine physician Dr Phillip J. Koo, medical oncologist Dr Scott T. Tagawa, and urologist Dr Jason M. Hafron discuss options for a patient with mCRPC who experienced progression after an ARPI.
Considerations for Providing PLUVICTO in a Urology Setting: A Conversation With Dr Finkelstein and Dr Pieczonka
Steven Finkelstein, MD, and Christopher Pieczonka, MD, discuss considerations and their experience for ordering and providing PLUVICTO to patients with PSMA+ mCRPC, prior to chemotherapy.
Earlier Use of PLUVICTO Prior to Chemotherapy: An Expert Dialogue
Watch Steven Finkelstein, MD, and Christopher Pieczonka, MD, talk about treating the first US patient to receive PLUVICTO after its approval for use prior to chemotherapy, along with other key considerations when discussing PLUVICTO with patients.
Expert Panel Perspectives on the Efficacy and Safety of PLUVICTO in PSMAfore
Watch Ulka Vaishampayan, MD, together with Chad Reichard, MD, and Gregg Franklin, MD, PhD, share insights on the PSMAfore trial, presenting the efficacy and safety data for PLUVICTO in patients with PSMA+ mCRPC.
Importance of Early Action in Care for Patients With mCRPC
Ulka Vaishampayan, MD, Chad Reichard, MD, and Gregg Franklin, MD, PhD, discuss the importance of early, effective treatment for mCRPC, the role of PSMA-PET imaging in patient selection, and how targeted radioligand therapies like PLUVICTO work.
Best Practices in Providing Treatment as a Multidisciplinary Team
Ulka Vaishampayan, MD, with Chad Reichard, MD, and Gregg Franklin, MD, PhD, share best practices in patient management and key PLUVICTO administration considerations, with a focus on the importance of a multidisciplinary approach for patients with mCRPC.
ARPI, androgen receptor pathway inhibitor; mCRPC, metastatic castration-resistant prostate cancer; mCSPC, metastatic castration-sensitive prostate cancer; PET, positron emission tomography; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.
Discover medical expert presentations about PLUVICTO from live events
Advancing PLUVICTO Therapy for the Right Patients
Glen Gejerman, MD, MBA, walks through what PLUVICTO therapy is at a live event, reviewing a summary of PLUVICTO data and presenting a hypothetical case of a patient with PSMA+ mCRPC, highlighting what types of patients are eligible for PLUVICTO therapy.
How to Communicate PLUVICTO Radiation Safety With Your Patients
Radiation oncologist Glen Gejerman, MD, MBA, presenting at a live event, provides insights and best practices for communicating radiation safety with patients receiving PLUVICTO.
Learn what medical experts have to say about PLUVICTO after ARPI and chemo1
Prostate Cancer & PLUVICTO Overview
Join Gordon Brown, DO, Mark Fleming, MD, Glen Gejerman, MD, and Christina Fareri, LPN, as they discuss PLUVICTO, a treatment option for patients with PSMA+ mCRPC.
VISION Efficacy and Safety
Join Gordon Brown, DO, Mark Fleming, MD, Glen Gejerman, MD, and Christina Fareri, LPN, as they review the results of the VISION trial.
PLUVICTO Dosing & Administration
Join Gordon Brown, DO, Mark Fleming, MD, Glen Gejerman, MD, and Christina Fareri, LPN, as they dive into the dosing and administration of PLUVICTO.
Prostate Cancer, PSMA, and PLUVICTO
Watch Neal Shore, MD, FACS, provide an overview of the role of PSMA-PET, and the targeted therapy PLUVICTO, in mCRPC.
Prostate Cancer, PSMA, and PLUVICTO
Join Mark Fleming, MD, in discussing PSMA-PET imaging and PLUVICTO, including its mechanism of action in the mCRPC space.
VISION Study Design
Watch Mark Fleming, MD, provide an overview of the study design for VISION, a trial assessing PLUVICTO in patients with mCRPC.
VISION Study Design
Join Neal Shore, MD, FACS, as he walks you through the VISION trial study design.
PLUVICTO Patient Identification
Neal Shore, MD, FACS, discusses which types of patients may be eligible for PLUVICTO based on the VISION trial.
PLUVICTO Patient Identification
Mark Fleming, MD, reviews the patient population in the VISION trial and discusses which types of patients may be eligible for PLUVICTO.
Read the latest clinical perspectives on PLUVICTO
The Bullseye: The VISION Study
In the first newsletter for HCPs considering PLUVICTO for patients, Neal Shore, MD, FACS, Mark Fleming, MD, Gordon Brown, DO, and Glen Gejerman, MD, provide perspectives on data from the VISION trial.
The Bullseye: The PSMAfore Study in Review
Jason Hafron, MD, Phillip Koo, MD, and Scott Tagawa, MD, share insights on the PSMAfore study in the second installment of The Bullseye.
The Bullseye: Third Edition
In the third installment of The Bullseye, Christopher Pieczonka, MD, and Steven Finkelstein, MD, describe their experience working with Novartis to provide PLUVICTO to patients and the use of PLUVICTO in patients with PSMA+ mCRPC prior to chemotherapy.